Discussion Workshop: Stem Cells

London , London
Friday, 06 May 2011

An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"  Linked In

Discussion Workshop: Stem Cells
Friday, 06 May 2011 09:00 - 17:00

The Penridge Suite
470 Bowes Road
London
London
N11 1NL
United Kingdom

Map and Directions
 

This event is discussion workshop, focused on the rapidly moving area of pluripotent cells. The aim is to bring together scientists to discuss important areas of work in this field with specific emphasis on practical technology. It offers participants a chance to explore aspects of the biology with the experts during rcancound table and one-to one discussions.

 

Meeting Chair: Dr Glyn Stacey, UK Stem Cell Bank, Division of Cell Biology and Imaging.

 

This event has CPD accreditation

On registration please submit your questions to the panel that will be asked by the chair on the day of the event

 

9:00 – 9:30        Registration

9:30 – 9:35        Introduction by Meeting Secretariat

 

9:30 – 9:45        Introduction by the Chair: Dr Glyn Stacey, UK Stem Cell Bank, Division of Cell Biology and Imaging

 

Talks by Invited Experts:

9:45 – 10:05        Cardiomyocytes from Human Pluripotent Stem Cells

Dr Chris Denning

Associate Professor & Reader in Stem Cell Biology

University of Nottingham, UK

The ability to maintain human pluripotent stem cells (hPSCs) for extended periods of time in culture and yet induce their differentiation to a wide range of cell types offers new opportunities in biomedicine. We will discuss our progress in producing human induced pluripotent stem cells from patients with genetic heart disease and our efforts to model disease using in vitro derived hPSC-cardiomyocytes, including in drug evaluation. We will also consider issues of scale up and defined culture / differentiation.

 

10:05 – 10:25      Differentiation of hESC/iPSC into Cardiomyocytes

Dr Nadire Ali

Senior Research Fellow

NHLI, Imperial College London, UK

ES cells (ESC) and iPSC are potentially good sources of cardiomyocytes. These cells and their derivatives can be used in several applications including as model systems, as a test bed for drug toxicity assays, screening for therapeutic targets, functional genomics studies and in future cell therapies. However, there are several hurdles which need to be overcome. These relate to pluripotent stem cells themselves, the methods of generating cardiomyocytes, and some aspects of the derived cardiac cells themselves. I will discuss these challenges, giving examples from our work and of others.

 

10:25 – 10:45      Characterisation of Human Pluripotent Stem Cells

Dr Paul Gokhale

Research Associate

Centre for Stem Cell Biology Sheffield, UK

Characterisation of pluripotent stem cells is critical if reliable cell lines are to be created for drug screening and therapeutic uses.  This talk will describe the characterisation of human embryonic stem cells that has been carried out by the International Stem Cells Initiative at the level of gene expression, imprinting, methylation, karyotype and copy number variation.  Attention will be drawn to key properties that mark bone fide human ES cells

 

10:45 – 11:15      Mid-morning Break

 

11:15 – 11:35      Principles of Cryopreservation

Dr Charlie Hunt

Operations Manger, Uk Stem Cell Bank

National Institute for Biological Standards and Control

An essential pre-requisite to the commercial and clinical application of stem cells are suitable and effective protocols for cryopreservation and long-term storage.  Whilst effective methods for cryopreservation have been developed for haematopoietic and mesenchymal stem cells, embryonic and iPS cells have proved more refractory.  Effective cryopreservation requires an understanding of the basic physical principles that underly the freeze/thaw process and the cells response to the imposition of such a process.  Basic principles and their application to stem cells will be discussed.

 

11:35 – 11:55      Of Mice (Rats) and Men - How Stem Cell Identities and Culture Systems have Evolved.

Dr Paul Bello

Head of Stem Cells & Media Sytems; Director of Technology Transfer

Stem Cell Sciences (UK) 

Recent publications have opened the door to a real possibility that human ES and iPS cells can be derived or re-programmed into the equivalent counterparts of true mouse pluripotent stem cells rather than what some researchers regard as ‘primed’ or more mature. Strikingly, the stem cell culture media conditions for this naive, ‘ground state’’ is becoming increasingly defined and reliant on discrete, potent kinase inhibitors rather than growth factors.  Indeed, there is now a distinct possibility that all mammalian pluripotent stem cells with germ line competency are attainable in inhibitor-based media.

 

11:55 – 12:15       The Evolution of iPS Technologies and Epigenetic Patterns Governing iPS Cell Fate

Dr. Rachel Craddock

Stem and Specialty Cell Culture Specialist

Merck Millipore

In 2006, Takahashi and Yamanaka published their seminal work in Cell, demonstrating four factors could be used to induce pluripotentcy in mouse fibroblasts. The potential for induced pluripotent stem (iPS) cells in reaseach and therapy was seemingly limitless; a renewalbe resource for studying complex mechanisms of pluripotentcy and differentation and perhaps more strikingly, the beginnings of a therapeutic solution to transplant rejection by using autologous tissue, reprogrammed to regenerate diseased tissue.

Five years later, an overwhelming amount of work has been published using this evolving technology, which strives to produce ever more faithful pluripotent cells from somatic tissue by reducing viral gene integration sites, or by use of proteins, small molecules and most recently miRNA to substitute reprogramming genes.

The underlying challenge is to generate iPS lines as faithful to physiological ES cells as possible. Currently, differences between iPS and ES are identified through comparison of transcriptomes, proteomes and methylomes as well as phenotypic surface and intracellular marker expression. Discussion has recently emerged as to whether differentiated iPS cells can reach the same functional maturity as physiological cells and epigenetic patterns have been implicated in developmental issues. 

This session is intended to open discussion into improvement of iPS models and how we can achieve functionally mature cells through differentiation of iPS cells.

 

12: 15                 Working Lunch

                           Please collect your lunch and take it to your discussion table (session 1)

 

12:30 – 13:45     Discussion Groups (Sessions 1, 2, 3 & 4)

·  Round table discussion groups (15 minutes each) will be held throughout the afternoon

·  Delegates will rotate so that they may participate in all the discussion tables

·  All delegates will also be allocated a session for visiting the exhibition stands

·  Where appropriate delegates will be able to bring their samples to the discussions

·  See end of agenda for description of discussion tables

 

13:45 – 14:05      Taking the Fight to Europe

Mr Julian Hitchcock

Consultant Solicitor, Field Fisher Waterhouse LLP

Director, CellFate

European stem cell science and regenerative medicine is subject to common rules and regulations.  An important case, before the European Court of Justice, shows why the sector needs to get its act together.

 

14:05– 14:25       Practical Problems in the Production of IPs Lines and their Selection

Dr Luodovic Vallier

MRC Senior Non-Clinical Fellow

Cambridge University, UK

Human pluripotent stem cells derived from reprogrammed somatic cells by overexpression of pluripotency factors (human Induced Pluripotent Stem Cells or hIPSCs) offer unmatched prospect for autologous cell based therapy and disease modelling in vitro. Indeed, they can be generated using cell obtained from patients with specific disease and then used to develop in vitro models allowing large scale studies impossible with primary cell cultures or with biopsy material. Here, we will discuss the practical aspects and challenges associated with hIPSCs derivation using the experience accumulated trough the derivation of 300 hIPSC lines from 50 patients

 

14:25 – 15:40      Discussion Groups (Sessions 5, 6, 7 and 8)

 

15:40 – 16:00      Stem Cell Growth, Adhesion and Differentiation

Dr Erik Miljan

Product Specialist, Stem Cells and Regenerative Medicine

AMS Biotechnology, UK

Stem cells are unspecialized cells that are capable of dividing and renewing themselves for long periods of time and can differentiate into many specialised cell types. When culturing stem cells, the optimisation of growth conditions is important in order to retain and maintain phenotypic and biological activity. The medium composition and extracellular matrix on which stem cells are maintained are crucial to most closely resemble their in vivo niche.  Differentiation of stem cells into the desired derivative represents a significant challenge. Ultimately, the goal is to produce robust and reliable stem cell differentiation pro-cesses that can be controlled within the laboratory.  Principles and regents to best support stem cell research will be discussed.

 

16:00 – 17:00      Question and Answer Session

                            This session will include summing up of the discussion tables and questions submitted prior to the meeting and throughout the day

 

17:00                   Chairman’s Summing Up

 

Discussion Table Sessions:

Table A: Sourcing Stem Cell Lines: Points to Consider

Hosted by Glyn Stacey, Head of the Division of Cell Biology and Imaging at NIBSC and Director for the UK Stem Cell Bank. His scientific background has been in microbiology and cancer research. From 1989-1998 he worked at Porton Down, UK, where he developed cell banking procedures and the development of cells for manufacture of medical products and cell-based diagnostic assays. At NIBSC he has developed a broad remit relating to the quality and safety of new biological medicines and therapies based on the use of human and animal cells. He has also acted as an advisor to the UK Department of Health and the World Health Organization. He coordinates the International Stem Cell Banking Initiative funded by a consortium of funding agencies from 20 countries. He has recently overseen the establishment of a new and expanded GMP facility for banking stem cell lines. He has published numerous scientific papers and books on cell banking and quality control.

 

Table B: Culture and Differentiation of Human Pluripotent Stem Cells

Hosted by Chris Denning, PhD in Cancer Gene Therapy at Beatson Institute for Cancer Research, University of Glasgow, 1997; Postdoctoral Research Fellow - gene targeting in mouse ES cells, Institute for Stem Cell Research, University of Edinburgh, 1997-1998; Postdoctoral Research Fellow - gene targeting in somatic cells; first targeted gene disruption in animals other than mouse, Roslin Institute 1998-2001; Principal Investigator, University of Nottingham, 2001-2003; Medical Research Council Fellow in Stem Cell Biology, University of Nottingham, 2003-2006; Lecturer in Stem Cell Biology, University of Nottingham, 2006-2008; Associate Professor & Reader in Stem Cell Biology, University of Nottingham 2008-

 

Table C: Challenges in the Generation of Cardiomyocytes from hESC and hiPSC  - What is Being Done to Overcome the Hurdles

Hosted by Nadire Ali, a Senior Research Fellow and Head of Embryonic Stem Cell Team at the NHLI, Imperial College London. She is also a member of BHF Centre of Research Excellence and serves on Editorial Board of Stem Cells International.  After her PhD (Biochemistry, London, 1983) she continued her studies with bone cells at UCL, RVC, ICRF at Lincoln Inn Fields and QMW. In 2000, she joined TERM Centre at Imperial and established the ESC Laboratory at NHLI (2003). Interested in optimising cardiomyocyte-generation from ESC/iPSC and studying their characteristics; purification of ESC-CM by non-genetic means; generate & study patient-specific-iPSC.

 

Table D: Characterisation of Human Pluripotent Stem Cells

Hosted by Dr Paul Gokhale, PhD, Tumour Cell Biology, 1999. Postdoctoral researcher with Prof. PW Andrews, University of Sheffield (1999-2005).  International Stem Cell Initiative (2005-present). ISCI-1 (2005-2008): Characterisation of Human embryonic stem cells and ISCI-2 (2008-2011): Identification of common genetic changes in Human embryonic stem cells.

 

Table E: Problems in Cryopreservation of Stem Cells

Hosted by Dr Charlie Hunt, whose background has been in the fields of cryobiology and tissue banking.  In 1978, he joined the MRC Medical Cryobiology Group at the University of Cambridge where his research involved the cryopreservation of cornea, pancreatic islets, and arteries. .In 1992, he and colleagues founded the East Anglia Tissue Bank; where he was responsible for the heart valve and autologous stem cell banking programs and developing skin and amniotic membrane banking.  In 2003, he took charge of the newly founded UK Stem Cell Bank at the National Institute for Biological Standards and Control, where he is currently the Operations Manager.

 

Table F: Refining & Redefining Stem Cell Culture

Hosted by Dr Paul Bello, Site Head, Director of Technology Transfer and Head of Stem Cells & Media Systems at Stem Cell Sciences (UK), a wholly owned subsidiary of StemCells Inc. (USA).  Prior to SCS, Dr Bello was BresaGen’s Human Stem Cell Studies Group Leader investigating ES cell pluripotency and differentiation protein networks, and also involved in human ES cell-based for Parkinsons’ therapy research, then became BresaGen’s Protein Pharmaceutical Division (ProtEcolTM Contract Manager for novel cGMP APIs inr clinical trials. Dr Bello was head of SCS' Research Centre (Australia), and since acquisition by StemCells Inc. (USA) in 2009, he is now Site Head, Director of Technology Transfer and Head of Stem Cells Systems responsible for stem cell technologies and products, while also contributing to the Company’s international research, collaborative and business efforts.

 

Table G: How to Improve Characterisation of IPS Cell Lines and Can Epigenetic Elements Improve the Fidelity of iPS Lines.

Hosted by Dr. Rachel Craddock, a Stem and Specialty Cell Culture Specialist with Merck Millipore since 2008.  She gained her PhD (2003) in ceramide/lipid raft signalling through death receptor complexes in unresolving inflammation at the Division of Immunity and Infection, University of Birmingham.  She then worked as a Post Doctoral Research Fellow at The Babraham Institute, Cambridge (2003 – 2005) – identifying mechanisms of oxidative stress in neuropsychiatric diseases and the development of a surrogate cell model for identifying signaling abnormalities in schizophrenia and at the Cambridge Centre for Neuro-psychiatric Research, Institute of biotechnology, University of Cambridge (2005 – 2007) – Identifying biomarkers in schizophrenia for development of diagnostic biosensors, using surrogate cell model system.

 

About our Invited Speakers:

Julian Hitchcock is an intellectual property lawyer specialising in the law of stem cells and regenerative medicine.  Formerly Executive Director of the East of England Stem Cell Network, Julian established CellFate in 2010 as an EESCN legacy project.  Julian is also an Associate of the PHG Foundation.

 

Ludovic Vallier is a MRC senior non-clinical fellow and a principal investigator in the Anne McLaren Laboratory for Regenerative Medicine (Cambridge University). He has developed a strong expertise on human Pluripotent Stem cells by discovering key mechanisms controlling their differentiation and pluripotency. His laboratory studies mechanisms controlling differentiation of pluripotent cells into endoderm from which the pancreas and liver originate. His overall objective is not only to acquire the knowledge necessary to control differentiation of pluripotent stem cells into endodermal cells but also to generate cell types for cell based therapy against diabetes and inherited metabolic diseases of the liver.

 

Erik Miljan has over 9 years experience in the Stem Cell Biotech sector, from intellectual property (IP) portfolio management through product development to regulatory approval. Initiated, implemented and delivered the operational and management strategy leading to the first ever stem cell based product approved for clinical trial in the UK in addition to delivering non-therapeutic stem cell products to market.  He has experience in International settings across both academia and industry in the US, Japan, Australia and the European Union.

 

Key words:

automation, human pluripotent stem cells, disease modelling, cardiomyocytes, genetic modification, hES cells (hESC), iPS cells (iPSC), freezing, vitrification, cryopreservation, stem cells, culture, defined media, cardiomyogenesis, hESC-CM, iPSC-CM, extracellular matrix, 3D culture, pluripotency assays, hIPSCs, reprogramming, differentiation, epigenetics, DNA methylation, cell therapies, patents, policy, Europe, embryo, lobbying

 



Don’t forget to sign up to Euroscicions e-newsletter at www.euroscicon.com/signup.htm to keep up to date with European Life Science news and events and to be notified of the follow up to this event

 

This meeting was organised by Euroscicon (www.euroscicon.com), a team of dedicated professionals working for the continuous improvement of technical knowledge transfer to all scientists. Euroscicon believe that they can make a positive difference to the quality of science by providing cutting edge information on new technological advancements to the scientific community. This is provided via our exceptional services to individual scientists, research institutions and industry.


 

Contact Details

Payment Instructions

  • For enquiries regarding payment email:  accounts@euroscicon.com

    You can pay by - Credit card, Cheque, Purchase Order or Bank transfer. 
    Payment must be received prior to the meeting

    Credit card
    You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered

    Cheque Payment 
    Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process).  After registration you will be emailed details of where to send your cheque.

    Purchase Order

    Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly

    Bank transfer 
    Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration.  
    After registration you will be emailed details of where transfer your money.

         Linked in

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5 4LQ. Trading address: BioPark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX



© 2019
Quick, easy and affordable online event registration and event management software for all event sizes.